(Q37021321)

17 August 2017

1 reference

title

Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside (English)

1 reference

17 August 2017

1 reference

Mario Di Napoli

1

1 reference

17 August 2017

Imtiaz M Shah

series ordinal

2

1 reference

17 August 2017

David A Stewart

series ordinal

3

1 reference

17 August 2017

publication date

1 December 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1693-1729

1 reference

Systematic review of incidence studies of Parkinson's disease

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Biomarkers in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Disturbance of iron metabolism in Parkinson's disease -- ultrasonography as a biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Biomarkers and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Stages in the development of Parkinson's disease-related pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Failure of the ubiquitin-proteasome system in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Proteasomal dysfunction in sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The proteasome: a proteolytic nanomachine of cell regulation and waste disposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The proteasome: structure, function, and role in the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Proteolysis: anytime, any place, anywhere?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Proteasome inhibition causes nigral degeneration with inclusion bodies in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Parkinson's disease: current and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Parkinson disease in twins: an etiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

A note of caution on correlation between sibling pairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

No evidence for heritability of Parkinson disease in Swedish twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Neurodegenerative diseases: an overview of environmental risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The role of early life environmental risk factors in Parkinson disease: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Molecular pathophysiology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

alpha-Synuclein locus triplication causes Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Variability and validity of polymorphism association studies in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Gene-environment interactions in sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Meta-analysis in genome-wide association datasets: strategies and application in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

21 January 2018

Genetic linkage studies

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Parkin: a multifaceted ubiquitin ligase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Linkage between the proteasome pathway and neurodegenerative diseases and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Pathophysiology of synuclein aggregation in Lewy body disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The biochemistry of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The role of alpha-synuclein in Parkinson's disease: insights from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Alpha-synuclein locus duplication as a cause of familial Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Alpha-synuclein multistate folding thermodynamics: implications for protein misfolding and aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

GM1 specifically interacts with alpha-synuclein and inhibits fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Alpha-synuclein overexpression reduces gap junctional intercellular communication in dopaminergic neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The role of alpha-synuclein in both neuroprotection and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Identification of G-protein coupled receptor kinase 2 in paired helical filaments and neurofibrillary tangles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Neurodegenerative disease: amyloid pores from pathogenic mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein--implications for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Parkinson's disease: piecing together a genetic jigsaw

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Complete genomic screen in Parkinson disease: evidence for multiple genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Parkin stabilizes microtubules through strong binding mediated by three independent domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Identification of far upstream element-binding protein-1 as an authentic Parkin substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

BAG5 inhibits parkin and enhances dopaminergic neuron degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Autophagy: many paths to the same end.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Protective roles for induction of autophagy in multiple proteinopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Autophagy and its possible roles in nervous system diseases, damage and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Chaperone-mediated autophagy in aging and neurodegeneration: lessons from alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Oxidative stress in neurodegeneration: cause or consequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Recessive Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Without DJ-1, the D2 receptor doesn't play

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Hereditary early-onset Parkinson's disease caused by mutations in PINK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

21 January 2018

Parkin blushed by PINK1.

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Expanding insights of mitochondrial dysfunction in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

21 January 2018

Mitochondrial disease

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Role of quinones in toxicology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Initiation of cancer and other diseases by catechol ortho-quinones: a unifying mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Mitochondrial dysfunction and possible treatments in Parkinson's disease--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Iron, brain ageing and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Inflammation as a causative factor in the aetiology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Clinical and pathologic features of families with LRRK2-associated Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Leucine-rich repeat kinase 2 associates with lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

LRRK2 expression linked to dopamine-innervated areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Distribution of PINK1 and LRRK2 in rat and mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

LRRK2 expression in normal and pathologic human brain and in human cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

LRRK2 in Parkinson's disease: protein domains and functional insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

The importance of LRRK2 mutations in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Neuroprotection by pharmacologic blockade of the GAPDH death cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Rationale for and use of NMDA receptor antagonists in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

GDNF family receptor complexes are emerging drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Chaperone-like activities of alpha-synuclein: alpha-synuclein assists enzyme activities of esterases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Protein misfolding disorders: pathogenesis and intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Stem cell treatment for Parkinson's disease: an update for 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Genetics of Parkinson disease: paradigm shifts and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Novel pharmacological targets for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Pathogenetic mechanisms of parkin in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Levodopa in the treatment of Parkinson's disease: current controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Deep brain stimulation in movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: three years follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Homeostatic and toxic mechanisms regulating manganese uptake, retention, and elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Familial Aggregation of Parkinson's Disease in Iceland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

No genetic association of the Ubiquitin Carboxy-terminal Hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

Collaborative Analysis of α-Synuclein Gene Promoter Variability and Parkinson Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.12.1693

10.1586/14737175.7.12.1693

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference